GNH USA

Europe — EMA

Kengrexal (Cangrelor Tetrasodium)

GNH USA supplies Kengrexal (Cangrelor), a P2Y12 receptor antagonist for rapid, reversible platelet inhibition during percutaneous coronary intervention.

Cangrelor Tetrasodium

Request sourcing

1
Pack/s

What is Cangrelor Tetrasodium?

Cangrelor, the active ingredient in Kengrexal, is a P2Y12 receptor antagonist presented as an injectable solution for intravenous use. It provides rapid, reversible platelet inhibition for patients undergoing percutaneous coronary intervention, helping to reduce periprocedural myocardial infarction and other ischemic complications.

GNH USA supplies Kengrexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Cangrelor Tetrasodium used for?

Cangrelor is used as an antiplatelet agent in the coronary intervention pathway.

- Percutaneous coronary intervention (PCI): Provides rapid, reversible platelet inhibition to reduce periprocedural myocardial infarction. - Adjunct to aspirin during PCI: Enhances antiplatelet effect when immediate platelet inhibition is required. - High‑risk PCI patients: Helps lower the incidence of ischemic complications during the procedure.

What are the side effects of Cangrelor Tetrasodium?

Cangrelor may cause a range of adverse reactions, most of which are related to its antiplatelet activity.

Common Side Effects: - Bleeding at the injection site - Mild bruising or ecchymosis - Hypotension - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Severe or uncontrolled bleeding - Thrombocytopenia - Anaphylactic or severe allergic reactions - Myocardial infarction despite therapy - Stroke or transient ischemic attack

What precautions apply to Cangrelor Tetrasodium?

When using Kengrexal, clinicians should observe several safety measures.

- Assess bleeding risk: Review patient history for recent hemorrhage or coagulopathy. - Monitor platelet function: Perform laboratory checks during and after infusion. - Avoid in active severe bleeding: Contraindicated in patients with uncontrolled hemorrhage. - Use with caution in hepatic impairment: Adjust monitoring as liver disease may affect metabolism. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

What does Cangrelor Tetrasodium interact with?

Cangrelor can interact with other agents that affect hemostasis.

Major Interactions (Avoid): - Concurrent use with other potent antiplatelet agents (e.g., clopidogrel, ticagrelor): may cause uncontrolled bleeding. - Combination with anticoagulants (e.g., heparin, warfarin) without monitoring: increased bleeding risk. - Use with glycoprotein IIb/IIIa inhibitors: additive antiplatelet effect leading to severe hemorrhage.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding tendency. - Selective serotonin reuptake inhibitors (SSRIs): potential for enhanced bleeding. - Proton pump inhibitors: generally safe but monitor for gastrointestinal bleeding.

Frequently asked questions

What is Kengrexal used for?+
Kengrexal is indicated as an adjunct to aspirin for patients undergoing percutaneous coronary intervention (PCI). It provides rapid, reversible inhibition of platelet aggregation, helping to reduce periprocedural myocardial infarction and other ischemic complications associated with the procedure.
How does Cangrelor work?+
Cangrelor acts by reversibly binding to the platelet P2Y12 ADP receptor. This blocks ADP‑mediated activation of the GPIIb/IIIa complex, preventing platelet activation and aggregation, which results in a fast‑acting antiplatelet effect that can be quickly discontinued when the infusion stops.
What is the usual dose of Kengrexal?+
The dosing regimen for Kengrexal is determined by the prescribing clinician based on the specific clinical scenario, patient characteristics, and procedural requirements. Healthcare professionals set the infusion rate and duration according to approved guidelines and individual patient needs.
Is Kengrexal safe in pregnancy or breastfeeding?+
Safety of Cangrelor in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.
How do I order Kengrexal from GNH USA?+
To order Kengrexal, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.
How does Kengrexal compare with the main alternative drug or class?+
Compared with oral P2Y12 inhibitors such as clopidogrel or ticagrelor, Kengrexal offers an intravenous route with a rapid onset of action and a short, reversible half‑life. This allows precise control of platelet inhibition during PCI, whereas oral agents have slower onset and longer duration, which may be less suitable for procedures requiring immediate platelet modulation.
What are the storage and handling requirements for Kengrexal?+
Kengrexal must be stored at 2‑8 °C in a refrigerator. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain ensures the stability and efficacy of the injectable solution.
How is Kengrexal administered?+
Kengrexal is administered intravenously by a qualified healthcare professional. It is typically given as a bolus followed by a continuous infusion during the PCI procedure, allowing rapid achievement of platelet inhibition that can be stopped immediately when the infusion ends.
What are the most serious risks to watch for with Kengrexal?+
The most serious risks include severe or uncontrolled bleeding, thrombocytopenia, and hypersensitivity reactions such as anaphylaxis. Clinicians should monitor patients closely for signs of bleeding, changes in platelet counts, and any allergic manifestations throughout the infusion.
Who should not use Kengrexal?+
Kengrexal should not be used in patients with active severe bleeding, known hypersensitivity to cangrelor or any component of the formulation, or in those where rapid platelet inhibition is contraindicated. Caution is also advised in patients with severe hepatic impairment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Cangrelor Tetrasodium
Route
Intravenous Use
Manufacturer
Chiesi Farmaceutici S.P.A.
Origin
EU

Related products

Kengrexal

Kengrexal

Cangrelor Tetrasodium

Chiesi Farmaceutici S.P.A.
EU
Kengrexal

Kengrexal

Cangrelor Tetrasodium

Chiesi Farmaceutici S.P.A.
EU
Kengrexal

Kengrexal

Cangrelor Tetrasodium

Chiesi Farmaceutici S.P.A.
EU